Tranzyme Announces Data Show ULISES 008 Did Not Meet Primary and Secondary Endpoints
Tranzyme Pharma (NASDAQ: TZYM) and Norgine B.V. announced Friday top-line results of the primary analysis of ULISES 008, the second of two Phase 3 pivotal trials evaluating ulimorelin in postoperative ileus. Consistent with the ULISES 007 data released in March 2012, ULISES 008 did not meet the primary and secondary endpoints as there was no statistical difference between the ulimorelin and placebo groups. The two trials were identical in design and population.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.